Mergers and Acquisitions in the IVD Market

  • ID: 4504614
  • Report
  • Region: Global
  • 85 Pages
  • Kalorama Information
1 of 4
This Report Looks at Market Transactions in Mergers and Acquisitions in the IVD Market, Recording Over 220 Acquisitions in the Diagnostics Industry From 2015 to March 2018

FEATURED COMPANIES

  • Abbott
  • Bruker
  • Curetis
  • IBM Healthcare/Watson
  • llumina
  • Quest and DiaSorin
  • MORE

As a means to more effectively address competitive pressures by capitalizing on economics of scale and scope, the in vitro diagnostics (IVD) industry continues to experience consolidations. Many of these transactions occur cross-border, particularly with U.S. and European companies seeking to enter Asia. Many also involve the acquisition of specific product lines or business units, rather than entire corporations. This report looks at market transactions in Mergers and Acquisitions in the IVD Market, recording over 220 acquisitions in the diagnostics industry from 2015 to March 2018.

Several of the newer technologies and trends in the IVD market are helping to drive acquisitions, often bringing acquiring companies into market segments or approaches to market segments that are new and innovative.

Examples of market segments or approaches to market segments in which there have been significant acquisitions include the following:

  • Gene Editing
  • Liquid Biopsy
  • Microbiome
  • Next-Generation Sequencing
  • Automation, and the Introduction of New, Large, Automated Platforms
  • Rapid Point-of-Care Testing with Single Pathogen Infectious Disease Tests
  • Connectivity
  • Looking to the East

Market leaders are not surprisingly often at the forefront of mergers and acquisitions (M&A) activities within the IVD market.

Top tier IVD companies who have been active in mergers and acquisitions include:

  • Roche
  • Abbott/Alere
  • Siemens
  • Beckman Coulter, Inc. / Danaher

Among the specific acquisitions discussed in the report are:

  • Abbott's acquisition of Alere and related divestures
  • Bio-Rad's acquisition of ddPCR developer RainDance
  • Konica Minolta's entry into the health and life sciences space with the acquisition of Ambry Genetics
  • Danaher’s acquisition of molecular diagnostics leader Cepheid

The U.S. tax legislation passed in December 2017 is expected to support increased M&A activity through significantly lower corporate taxes that will provide capital for deals. This, combined with continued low interest rates and opportunities for increasing profits and/or revenues through M&A, will support M&A activity moving forward.

The information presented in this report is the result of data gathered from government reports, company product literature and other corporate brochures and documents, as well as information found in the scientific and trade press.

READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Abbott
  • Bruker
  • Curetis
  • IBM Healthcare/Watson
  • llumina
  • Quest and DiaSorin
  • MORE

1. Executive Summary

  • The Market Landscape
  • Roche
  • Abbott/Alere
  • Siemens
  • Beckman Coulter, Inc. / Danaher
  • The Changing Landscape
  • Market Trends Helping to Drive Mergers and Acquisitions
  • Gene Editing
  • Liquid Biopsy
  • Next-Generation Sequencing
  • Automation, and the Introduction of New, Large, Automated Platforms
  • Rapid Point-of-Care Testing with Single Pathogen Infectious Disease Tests
  • Connectivity
  • Looking to the East
  • Microbiome
  • Methodology

2. IVD Mergers and Acquisitions

  • Overview: The IVD Industry - A Changing Market
  • M&A in Selected Markets
  • Lab-Developed Test (LDT) Services Market
  • The PCR/NAAT Market
    • Table Selected Acquisitions of Diagnostic Companies, from 2017 to mid-March 2018
  • Selected 2017 / 2018 Acquisitions of Note
  • Abbott: Acquisitions, Divestures and the Alere Deal
  • Siemens' Divestiture of a Portion of Its Healthcare Business, Siemens Healthineers
  • Roche Active in M&A, Part 1
  • Celgene Active in Early 2018
  • Agilent Makes Cell Analysis Buy
  • Charles River Labs Acquires KWS BioTest
  • Early 2018 M&A Activity in Biotech -- Sanofi Buys Bioverativ, Ablynx
  • Chembio Diagnostics Acquires Malaysian Firm RVR Diagnostics
  • Konica Minolta Acquires Ambry Genetics
  • Quidel Amends Alere Deal
  • Thermo Completes Patheon Acquisition
  • Agilent Acquires the Molecular and Sample Barcoding Patent Portfolios of Population Genetics
  • Enterome and Nestle Health Science Form Microbiome Diagnostics Partners
  • PerkinElmer Expansion via Tulip and Euroimmun Acquisitions
  • Sysmex Acquires Oxford Gene Technology (OGT)
  • LabCorp Completes PAML Acquisition
  • Cathay Fortune International Acquires Molecular Diagnostics Firm Epigenomics
  • Bio-Rad Acquires ddPCR Developer RainDance
  • QIAGEN M&A Activity
  • Agilent Completes the Acquisition of Multiplicom
  • Grifols Acquires NAT Donor Screening Unit from Hologic
  • Johnson & Johnson Diabetes Business Attracts Chinese Interest
  • The 2015-2016 Market
    • Table Selected Acquisitions of Diagnostic Companies, 2015-2016
  • Selected 2015 / 2016 Acquisitions of Note
  • Roche Active in M&A, Part 2
  • Danaher's Acquires Molecular Diagnostics Leader Cepheid for Nearly $4 Billion
  • Abbott Acquires St. Jude Medical, Adds Patient Monitoring and Neurostimulation Strength
  • Thermo Fisher Scientific Completes Major Deals in 2016
  • Beckman Coulter Acquires Siemens Healthcare Diagnostics' Clinical Microbiology Business
  • Becton Dickinson (BD) Prepares Its Entrance into Sequencing with Cellular Research Acquisition
  • Founding CTC Technology Finds Another Home
  • Curetis Acquires Real-Time qPCR-based Gyronimo Platform from Carpegen GmbH and Systec GmbH
  • Bruker Acquires Nucleic Acid Testing Assays and Syndromic Panel Technology
  • LabCorp Completes Its Acquisition of Sequenom
  • Curetis Acquires Asset from Siemens Technology Accelerator
  • Debiopharm Group Acquires GenePOC
  • Luminex Seeks to Leverage Nanosphere's Verigene Platform
  • Siemens Expands Its Diagnostics Portfolio
  • Quest and DiaSorin to Focus on Key Markets Following Acquisition Deal
  • Immucor Acquires Sirona Genomics
  • llumina Establishes GRAIL Bio
  • Charles River Acquires Agilux, WIL Research, and Oncotest
  • IBM Healthcare/Watson Continues Expansion
  • BD Acquires CareFusion
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Abbott
  • Agilent
  • Ambry Genetics
  • Becton Dickinson (BD)
  • Bio-Rad
  • Bruker
  • CareFusion
  • Cathay Fortune International
  • Celgene
  • Charles River Labs
  • Chembio Diagnostics
  • Curetis
  • Danaher
  • Debiopharm Group
  • Enterome
  • Grifols
  • IBM Healthcare/Watson
  • Immucor
  • Johnson & Johnson
  • Konica Minolta
  • LabCorp
  • llumina
  • Luminex
  • Nestle Health Science
  • Oxford Gene Technology (OGT)
  • PerkinElmer
  • QIAGEN
  • Quest and DiaSorin
  • Quidel
  • Roche
  • RVR Diagnostics
  • Sanofi
  • Siemens
  • Sysmex
  • Thermo Fisher Scientific
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll